T2 Biosystems (TTOO) Q4 2024 earnings summary

Executive summary

• Achieved record sepsis product revenues in Q4 2024 ($2.3M) and full year 2024 ($8.3M), up 37% and 23% year-over-year, respectively, driven by strong sepsis test sales.

• Expanded global installed base with 27 T2Dx Instruments sold in 2024, including 23 internationally and 4 in the U.S.

• Entered exclusive U.S. distribution agreement with Cardinal Health for key sepsis detection products.

• Advanced product pipeline with FDA 510(k) clearances and progress on new diagnostic panels.

Financial highlights

• Q4 2024 product revenue reached $2.3M, a 37% increase year-over-year; full year 2024 product revenue was $8.3M, up 23% year-over-year.

• Cash and cash equivalents totaled $1.7M as of December 31, 2024.

• Converted $30M of term loan into common stock, reducing debt and quarterly interest payments by approximately 80% over the past year.

Outlook and guidance

• Expects exclusive Cardinal Health agreement to drive commercial growth in 2025.

• Plans to accelerate product sales, enhance operations, and advance new product pipeline in 2025.

• Anticipates FDA 510(k) submission for T2Resistance Panel in Q1 2025.